Predictive Oncology has appointed Nancy Chung-Welch, Charles Nuzum, and Greg St. Clair as independent directors to the firm. While Nuzum will serve on Predictive's audit committee, the firm noted that the other directors will join committees as soon as possible.
Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors. She previously served as director of business development at Cell Signaling Technology, as well as a director of business development at Thermo Fisher Scientific. She has also served as a technical marketing manager at Fisher Scientific.
Nuzum currently provides project-based financial consulting services to companies including McKesson, BioMarin, and AutoDesk. He serves on the board of directors of Dakshidin, NanoSynx, and Worldwide Structures. He previously cofounded and served as CFO of Tyburn Group. Prior to Tyburn, Nuzum served as controller of Merck KgaA pharmaceutical manufacturing subsidiary Dely. Before working at Dely, he served as cofounder, executive VP, and CFO of SCV Financial Services.
St. Clair is the founder and managing member of SunStone Consulting. Prior to SunStone, he served as national VP of CGI, ImrGlobal, and Orion Consulting. He also served as a national director for Coopers & Lybrand.